Tvardi Therapeutics
TVRD
93 hedge funds and large institutions have $101M invested in Tvardi Therapeutics in 2016 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 35 increasing their positions, 29 reducing their positions, and 15 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less call options, than puts
Call options by funds: $91K | Put options by funds: $98K
2% less funds holding
Funds holding: 95 → 93 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
70% less capital invested
Capital invested by funds: $341M → $101M (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.55M |
| 2 |
RCP
Rho Capital Partners
New York
|
+$3.32M |
| 3 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$3.14M |
| 4 |
JP Morgan Chase
New York
|
+$1.36M |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.9M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$15.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.94M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$4.16M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.33M |
TVRD Hedge Fund Activity: Q1 2016 in Review
93 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2016, worth a combined $101M — down 70% from $341M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TVRD and 13 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 35 added.
The largest buyer was Opaleye Management, adding an estimated $3.55M. The largest seller was Fidelity Investments, cutting an estimated $18.9M.
- 93 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2016, down from 95 in Q4 2015.
- Funds reported $101M of Tvardi Therapeutics stock for Q1 2016, down 70% quarter-over-quarter.
- 13 funds opened new Tvardi Therapeutics positions in Q1 2016 and 15 closed out, a net change of -2 holders.
- The largest Tvardi Therapeutics buyer in Q1 2016 was Opaleye Management, an estimated $3.55M added.
- The largest Tvardi Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $18.9M sold.
Based on aggregated 13F filings for Q1 2016.